Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?

Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9

(2019) Nitesh K. Kunda et al.   Human Vaccines & Immunotherapeutics

Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer

(2019) Lukai Zhai et al.   ANTIVIRAL RESEARCH

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity

(2019) C. Schellenbacher et al.   VACCINE

A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types

(2019) Ting Zhang et al.   VACCINE

A Current Update on Human Papillomavirus-Associated Head and Neck Cancers

(2019) Ebenezer Tumban   Viruses-Basel

Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses

(2018) Marija Vujadinovic et al.   VACCINE

Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice

(2018) Xue Chen et al.   Human Vaccines & Immunotherapeutics

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice

(2018) Viswanathan Ramasamy et al.   PLoS Neglected Tropical Diseases

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study

(2018) Vladimir Gilca et al.   Human Vaccines & Immunotherapeutics

Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen

(2018) Andrew G. Diamos et al.   VACCINE

HPV vaccines – A review of the first decade

(2017) Diane M. Harper et al.   GYNECOLOGIC ONCOLOGY

Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses

(2017) Somayeh Pouyanfard et al.   JOURNAL OF VIROLOGY

Cryoelectron Microscopy Maps of Human Papillomavirus 16 Reveal L2 Densities and Heparin Binding Site

(2017) Jian Guan et al.   STRUCTURE

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes

(2017) Kirill Kalnin et al.   VACCINE

Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17–36

(2017) Stephanie Bywaters et al.   Viruses-Basel

Subcellular Trafficking of the Papillomavirus Genome during Initial Infection: The Remarkable Abilities of Minor Capsid Protein L2

(2017) Samuel Campos   Viruses-Basel

Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles

(2017) Gloria Spagnoli et al.   Scientific Reports

VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation

(2017) Seth M. Daly et al.   Scientific Reports

The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses

(2017) Merryn Voysey et al.   JAMA Pediatrics

Virus like particles as a platform for cancer vaccine development

(2017) Hui Kian Ong et al.   PeerJ

Gardasil-9: A global survey of projected efficacy

(2016) Lukai Zhai et al.   ANTIVIRAL RESEARCH

The effect of preexisting anti-carrier immunity on subsequent responses to CRM197or Qb-VLP conjugate vaccines

(2016) Michael J. McCluskie et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles

(2016) Mathieu Boxus et al.   JOURNAL OF VIROLOGY

Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza

(2016) Veronika I. Zarnitsyna et al.   PLoS Pathogens

Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine

(2015) H. Seitz et al.   Cancer Prevention Research

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

(2015) Elmar A. Joura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17–36 epitopes

(2015) Subhashini Jagu et al.   VACCINE

A cholesterol-lowering VLP vaccine that targets PCSK9

(2015) Erin Crossey et al.   VACCINE

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2

(2015) Ebenezer Tumban et al.   VACCINE

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach

(2015) Wai-Hong Wu et al.   Virology Journal

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus Types

(2015) Bettina Huber et al.   PLoS One

The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine

(2014) Mitchell Tyler et al.   BIOTECHNOLOGY AND BIOENGINEERING

Durability of Antibody Response Against Hepatitis B Virus in Healthcare Workers Vaccinated as Adults

(2014) Naveen Gara et al.   CLINICAL INFECTIOUS DISEASES

Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model

(2014) Bryce Chackerian et al.   JOURNAL OF IMMUNOLOGY

Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing

(2014) Mitchell Tyler et al.   VACCINE

A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses

(2014) Hanna Seitz et al.   VACCINE

Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial

(2013) L. Toft et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses

(2013) Christina Schellenbacher et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

M2e-Displaying Virus-Like Particles with Associated RNA Promote T Helper 1 Type Adaptive Immunity against Influenza A

(2013) Lorena Itatí Ibañez et al.   PLoS One

A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvants

(2013) Ebenezer Tumban et al.   VACCINE

L2, the minor capsid protein of papillomavirus

(2013) Joshua W. Wang et al.   VIROLOGY

Virus-induced humoral immunity: on how B cell responses are initiated

(2013) Franziska Zabel et al.   Current Opinion in Virology

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector

(2013) Marlyse C. Knuchel et al.   Human Vaccines & Immunotherapeutics

Construction and Characterization of Virus-Like Particles: A Review

(2012) Andris Zeltins   MOLECULAR BIOTECHNOLOGY

Development of AAVLP(HPV16/31L2) Particles as Broadly Protective HPV Vaccine Candidate

(2012) Karen Nieto et al.   PLoS One

VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus

(2012) Ebenezer Tumban et al.   PLoS One

Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity

(2012) D. E. Zak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Present and Future of Peptide Vaccines for Cancer

(2011) Craig L. Slingluff   CANCER JOURNAL

A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2

(2011) Ebenezer Tumban et al.   PLoS One

Thermal Stability of RNA Phage Virus-Like Particles Displaying Foreign Peptides

(2011) Jerri C Caldeira et al.   JOURNAL OF NANOBIOTECHNOLOGY

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

(2010) Subhashini Jagu et al.   VACCINE

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7

(2010) Jerri do Carmo Caldeira et al.   VACCINE

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

(2009) Cosette M. Wheeler et al.   JOURNAL OF INFECTIOUS DISEASES

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years

(2009) Darron R. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines

(2009) Subhashini Jagu et al.   JNCI-Journal of the National Cancer Institute

Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines

(2009) C. Schellenbacher et al.   JOURNAL OF VIROLOGY

The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding

(2009) R. C. Kines et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure and stability of icosahedral particles of a covalent coat protein dimer of bacteriophage MS2

(2009) Pavel Plevka et al.   PROTEIN SCIENCE

Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin

(2009) Ivonne Rubio et al.   VACCINE

Nanoparticles target distinct dendritic cell populations according to their size

(2008) Vania Manolova et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

(2008) Kazunari Kondo et al.   JOURNAL OF MEDICAL VIROLOGY

Immunogenic Display of Diverse Peptides on Virus-like Particles of RNA Phage MS2

(2008) David S. Peabody et al.   JOURNAL OF MOLECULAR BIOLOGY

Arrangement of L2 within the Papillomavirus Capsid

(2008) C. B. Buck et al.   JOURNAL OF VIROLOGY

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2

(2008) H. H. Alphs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transient expression of HPV16 E7 peptide (aa 44–60) and HPV16 L2 peptide (aa 108–120) on chimeric potyvirus-like particles using Potato virus X-based vector

(2007) Noemi Čeřovská et al.   PROTEIN EXPRESSION AND PURIFICATION